Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Capecitabine and Gemcitabine Variant #01 | — | R 6 309 | 21d | — | ~7.9 mo | ~6 | ~R 37 856 PFS proxy · indirect | 6 |
Capecitabine and RT Variant #01 | — | R 4 922 | 35d | — | — | ~3 | ~R 8 817 PFS proxy · indirect | 2 |
GemOx Variant #01 | — | R 2 937 | 14d | — | ~9.3 mo | ~7 | ~R 20 560 PFS proxy · indirect | 2 |
Capecitabine monotherapy Variant #01 | — | R 1 039 | 21d | ~5.7 mo | ~7.5 mo | ~35 | ~R 36 351 PFS proxy · indirect | 11 |
Observation Partial | — | — | — | ~3.4 mo | ~36.1 mo | — | — | 18 |
S-1 monotherapy Variant #01 Partial | — | — | 21d | ~1.7 mo | ~10.5 mo | ~2 | — | 13 |
6 of 6 regimens shown